Paul Baas1, Arnaud Scherpereel2, Anna K Nowak3, Nobukazu Fujimoto4, Solange Peters5, Anne S Tsao6, Aaron S Mansfield7, Sanjay Popat8, Thierry Jahan9, Scott Antonia10, Youssef Oulkhouir11, Yolanda Bautista12, Robin Cornelissen13, Laurent Greillier14, Francesco Grossi15, Dariusz Kowalski16, Jerónimo Rodríguez-Cid17, Praveen Aanur18, Abderrahim Oukessou18, Christine Baudelet18, Gérard Zalcman19. 1. The Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, Netherlands. Electronic address: p.baas@nki.nl. 2. Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France. 3. Medical School, University of Western Australia Perth, WA, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia. 4. Okayama Rosai Hospital, Okayama, Japan. 5. Lausanne University Hospital, Lausanne, Switzerland. 6. MD Anderson Cancer Center, Houston, TX, USA. 7. Mayo Clinic, Rochester, MN, USA. 8. Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK. 9. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. 10. H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 11. Hôpital Côte de Nacre CHU de Caen, Caen, France. 12. Centro Médico Nacional Siglo XXI, Mexico City, Mexico. 13. Erasmus MC Cancer Institute, Rotterdam, Netherlands. 14. Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France. 15. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 16. Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 17. Centro Oncológico, Médica Sur-Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico. 18. Bristol Myers Squibb, Princeton, NJ, USA. 19. Bichat-Claude Bernard University Hospital, AP-HP, Université de Paris, Paris, France.
Abstract
BACKGROUND: Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell lung cancer. We hypothesised that this regimen would improve overall survival in MPM. METHODS: This open-label, randomised, phase 3 study (CheckMate 743) was run at 103 hospitals across 21 countries. Eligible individuals were aged 18 years and older, with previously untreated, histologically confirmed unresectable MPM, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible participants were randomly assigned (1:1) to nivolumab (3 mg/kg intravenously once every 2 weeks) plus ipilimumab (1 mg/kg intravenously once every 6 weeks) for up to 2 years, or platinum plus pemetrexed chemotherapy (pemetrexed [500 mg/m2 intravenously] plus cisplatin [75 mg/m2 intravenously] or carboplatin [area under the concentration-time curve 5 mg/mL per min intravenously]) once every 3 weeks for up to six cycles. The primary endpoint was overall survival among all participants randomly assigned to treatment, and safety was assessed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT02899299, and is closed to accrual. FINDINGS:Between Nov 29, 2016, and April 28, 2018, 713 patients were enrolled, of whom 605 were randomly assigned to either nivolumab plus ipilimumab (n=303) or chemotherapy (n=302). 467 (77%) of 605 participants weremale and median age was 69 years (IQR 64-75). At the prespecified interim analysis (database lock April 3, 2020; median follow-up of 29·7 months [IQR 26·7-32·9]), nivolumab plus ipilimumab significantly extended overall survival versus chemotherapy (median overall survival 18·1 months [95% CI 16·8-21·4] vs 14·1 months [12·4-16·2]; hazard ratio 0·74 [96·6% CI 0·60-0·91]; p=0·0020). 2-year overall survival rates were 41% (95% CI 35·1-46·5) in the nivolumab plus ipilimumab group and 27% (21·9-32·4) in the chemotherapy group. Grade 3-4 treatment-related adverse events were reported in 91 (30%) of 300 patients treated with nivolumab plus ipilimumab and 91 (32%) of 284 treated with chemotherapy. Three (1%) treatment-related deaths occurred in the nivolumab plus ipilimumab group (pneumonitis, encephalitis, and heart failure) and one (<1%) in the chemotherapy group (myelosuppression). INTERPRETATION:Nivolumab plus ipilimumab provided significant and clinically meaningful improvements in overall survival versus standard-of-care chemotherapy, supporting the use of this first-in-class regimen that has been approved in the USA as of October, 2020, for previously untreated unresectable MPM. FUNDING: Bristol Myers Squibb.
RCT Entities:
BACKGROUND: Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell lung cancer. We hypothesised that this regimen would improve overall survival in MPM. METHODS: This open-label, randomised, phase 3 study (CheckMate 743) was run at 103 hospitals across 21 countries. Eligible individuals were aged 18 years and older, with previously untreated, histologically confirmed unresectable MPM, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible participants were randomly assigned (1:1) to nivolumab (3 mg/kg intravenously once every 2 weeks) plus ipilimumab (1 mg/kg intravenously once every 6 weeks) for up to 2 years, or platinum plus pemetrexed chemotherapy (pemetrexed [500 mg/m2 intravenously] plus cisplatin [75 mg/m2 intravenously] or carboplatin [area under the concentration-time curve 5 mg/mL per min intravenously]) once every 3 weeks for up to six cycles. The primary endpoint was overall survival among all participants randomly assigned to treatment, and safety was assessed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT02899299, and is closed to accrual. FINDINGS: Between Nov 29, 2016, and April 28, 2018, 713 patients were enrolled, of whom 605 were randomly assigned to either nivolumab plus ipilimumab (n=303) or chemotherapy (n=302). 467 (77%) of 605 participants were male and median age was 69 years (IQR 64-75). At the prespecified interim analysis (database lock April 3, 2020; median follow-up of 29·7 months [IQR 26·7-32·9]), nivolumab plus ipilimumab significantly extended overall survival versus chemotherapy (median overall survival 18·1 months [95% CI 16·8-21·4] vs 14·1 months [12·4-16·2]; hazard ratio 0·74 [96·6% CI 0·60-0·91]; p=0·0020). 2-year overall survival rates were 41% (95% CI 35·1-46·5) in the nivolumab plus ipilimumab group and 27% (21·9-32·4) in the chemotherapy group. Grade 3-4 treatment-related adverse events were reported in 91 (30%) of 300 patients treated with nivolumab plus ipilimumab and 91 (32%) of 284 treated with chemotherapy. Three (1%) treatment-related deaths occurred in the nivolumab plus ipilimumab group (pneumonitis, encephalitis, and heart failure) and one (<1%) in the chemotherapy group (myelosuppression). INTERPRETATION:Nivolumab plus ipilimumab provided significant and clinically meaningful improvements in overall survival versus standard-of-care chemotherapy, supporting the use of this first-in-class regimen that has been approved in the USA as of October, 2020, for previously untreated unresectable MPM. FUNDING: Bristol Myers Squibb.
Authors: L Gutierrez-Sainz; P Cruz; S Martinez-Recio; O Higuera; M I Esteban-Rodriguez; F Arias-Lotto; R A Gonzalez; J De Castro-Carpeño Journal: Clin Transl Oncol Date: 2021-04-10 Impact factor: 3.405
Authors: Michael B Foote; Jinru Shia; Marjorie G Zauderer; Garrett M Nash; Andrea Cercek Journal: J Immunother Date: 2022 Feb-Mar 01 Impact factor: 4.456
Authors: Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee Journal: Front Oncol Date: 2021-04-27 Impact factor: 6.244
Authors: Gauri R Varadhachary; Daniel M Halperin; Kanwal Raghav; Suyu Liu; Michael J Overman; Anneleis F Willett; Mark Knafl; Szu-Chin Fu; Anais Malpica; Seema Prasad; Richard E Royal; Christopher P Scally; Paul F Mansfield; Ignacio I Wistuba; Andrew P Futreal; Dipen M Maru; Luisa M Solis Soto; Edwin R Parra Cuentas; Honglei Chen; Pamela Villalobos; Anuj Verma; Armeen Mahvash; Patrick Hwu; Patricia Cortazar; Edward McKenna; Cindy Yun; Shannon Dervin; Katja Schulze; Walter C Darbonne; Ajaykumar C Morani; Scott Kopetz; Keith F Fournier; Scott E Woodman; James C Yao Journal: Cancer Discov Date: 2021-07-14 Impact factor: 39.397
Authors: Prasad S Adusumilli; Marjorie G Zauderer; Isabelle Rivière; Stephen B Solomon; Valerie W Rusch; Roisin E O'Cearbhaill; Amy Zhu; Waseem Cheema; Navin K Chintala; Elizabeth Halton; John Pineda; Rocio Perez-Johnston; Kay See Tan; Bobby Daly; Jose A Araujo Filho; Daniel Ngai; Erin McGee; Alain Vincent; Claudia Diamonte; Jennifer L Sauter; Shanu Modi; Devanjan Sikder; Brigitte Senechal; Xiuyan Wang; William D Travis; Mithat Gönen; Charles M Rudin; Renier J Brentjens; David R Jones; Michel Sadelain Journal: Cancer Discov Date: 2021-07-15 Impact factor: 39.397